Novartis

Latest stories

1h
The News & Observer
GSK names new head of consumer healthcaremaximize the future opportunities we have with our brands,” Witty said in a sta
GSK names new head of consumer healthcare
The News & Observer / Posted an hour ago
maximize the future opportunities we have with our brands,” Witty said in a statement. McNamara joined GSK last year from Novartis upon completion of the transaction in which GSK acquired Novartis’s global vaccines business and created a joint... Read more
1h
Times of Malta
GlaxoSmithKline to pay $20 million to settle US foreign bribery caselatest case to emerge from an industry-wide sweep that started in 2010. Since
GlaxoSmithKline to pay $20 million to settle US foreign bribery case
Times of Malta / Posted an hour ago
latest case to emerge from an industry-wide sweep that started in 2010. Since then, a number of other companies including Novartis AG and AstraZeneca Plc have also settled similar charges with the SEC. In the case of GlaxoSmithKline, the SEC... Read more
4h
FOX Business
Here's Why Ophthotech Corporation Is Dropping TodayOphthotech to deliver good news when it reports data from its phase 3 clinical
Here's Why Ophthotech Corporation Is Dropping Today
FOX Business / Posted 4 hours ago
Ophthotech to deliver good news when it reports data from its phase 3 clinical trial evaluating Fovista in combination with Novartis' Lucentis in the fourth quarter. In phase 2b studies, the combination therapy showed a 62% improvement when compared... Read more
4h
FOX Business
Here's Why Ophthotech Corporation Is Dropping TodayOphthotech to deliver good news when it reports data from its phase 3 clinical
Here's Why Ophthotech Corporation Is Dropping Today
FOX Business / Posted 4 hours ago
Ophthotech to deliver good news when it reports data from its phase 3 clinical trial evaluating Fovista in combination with Novartis' Lucentis in the fourth quarter. In phase 2b studies, the combination therapy showed a 62% improvement when compared... Read more
6h
FOX Business
Is It Too Late To Get In On This Millionaire-Maker Stock?have driven royalty revenues over 50% higher in the first half of this year com
Is It Too Late To Get In On This Millionaire-Maker Stock?
FOX Business / Posted 6 hours ago
have driven royalty revenues over 50% higher in the first half of this year compared with the same period of 2015: Novartis' Promacta, which has notched year-to-date sales of $289 million. Amgen's Kyprolis, which has achieved global... Read more
6h
FOX Business
Is It Too Late To Get In On This Millionaire-Maker Stock?have driven royalty revenues over 50% higher in the first half of this year com
Is It Too Late To Get In On This Millionaire-Maker Stock?
FOX Business / Posted 6 hours ago
have driven royalty revenues over 50% higher in the first half of this year compared with the same period of 2015: Novartis' Promacta, which has notched year-to-date sales of $289 million. Amgen's Kyprolis, which has achieved global... Read more
8h
PhotonicsOnline
“Smart” Contact Lens Uses Optical Biosensing To Detect Glucosenon-invasive glucose monitor, something Shih calls “a needle in a haystack chal
“Smart” Contact Lens Uses Optical Biosensing To Detect Glucose
PhotonicsOnline / Posted 8 hours ago
non-invasive glucose monitor, something Shih calls “a needle in a haystack challenge.” For the past two years, Verily and Novartis have been working together to develop a “smart contact lens,” including a model with an integrated glucose sensor.... Read more
10h
Business Wire
SQZ Biotech Announces $16 Million Series B Funding Round Led by NanoDimension and Polaris Partnersdevelopment and strategic partnerships. Prior to joining SQZ in June, Kris led
SQZ Biotech Announces $16 Million Series B Funding Round Led by NanoDimension and Polaris Partners
Business Wire / Posted 10 hours ago
development and strategic partnerships. Prior to joining SQZ in June, Kris led the US commercial model development for Novartis' CAR T-cell products. Kris has more than a dozen years of experience at Novartis and McKinsey & Co. in commercial,... Read more
15h
Investors Chronicle
The next blockbuster drugspartnering its respiratory products and receiving royalty payments. Its Breezha
The next blockbuster drugs
Investors Chronicle / Posted 15 hours ago
partnering its respiratory products and receiving royalty payments. Its Breezhaler range generates significant sales for Novartis (CH:NOVN), while GSK's Ellipta is edging towards blockbuster status having generated £220m of revenue in the second... Read more
2 related stories
21h
Pacific Coast Business Times
Amgen announces positive results for migraine drugbiotech giant Amgen announced positive data from a phase 3 study of a new migra
Amgen announces positive results for migraine drug
Pacific Coast Business Times / Posted 21 hours ago
biotech giant Amgen announced positive data from a phase 3 study of a new migraine drug co-developed with competitor Novartis. Amgen said in a news release that, after 12 weeks, Erenumab showed a significant reduction in monthly migraine... Read more
1d
Channel NewsAsia
After CEO move, GSK picks ex-Novartis exec to head consumer unitLONDON: GlaxoSmithKline has promoted a former Novartis executive to lead its co
After CEO move, GSK picks ex-Novartis exec to head consumer unit
Channel NewsAsia / Posted yesterday
LONDON: GlaxoSmithKline has promoted a former Novartis executive to lead its consumer healthcare business, following the appointment last week of the unit's previous head, Emma Walmsley, as CEO designate of the drugmaker. The British group said on... Read more
1d
Boston Globe
Biotechs leverage patient groups in drug developmentfor other companies working on rare disease medicines remains to be seen. One p
Biotechs leverage patient groups in drug development
Boston Globe / Posted yesterday
for other companies working on rare disease medicines remains to be seen. One panelist at Tuesday’s patient summit, at the Novartis Institutes for BioMedical Research in Cambridge, cautioned drug makers to keep some distance from patients when... Read more
5 related stories
2d
FOX Business
Will Celgene Depose Biogen To Become Top Dog In Multiple Sclerosis?the biggest seller is Biogen's Tecfidera -- with worldwide sales last year comi
Will Celgene Depose Biogen To Become Top Dog In Multiple Sclerosis?
FOX Business / Posted 2 days ago
the biggest seller is Biogen's Tecfidera -- with worldwide sales last year coming in just shy of $4 billion -- followed by Novartis' Gilenya and Sanofi's rapidly growing Aubagio. Ozanimod is part of the exciting new category of S1P modulators,... Read more
2d
FOX Business
Will Celgene Depose Biogen To Become Top Dog In Multiple Sclerosis?the biggest seller is Biogen's Tecfidera -- with worldwide sales last year comi
Will Celgene Depose Biogen To Become Top Dog In Multiple Sclerosis?
FOX Business / Posted 2 days ago
the biggest seller is Biogen's Tecfidera -- with worldwide sales last year coming in just shy of $4 billion -- followed by Novartis' Gilenya and Sanofi's rapidly growing Aubagio.More From Fool.com Ozanimod is part of the exciting new category of... Read more
3d
Business Wire
Global Gastric Cancer Market Analysis 2016 - Forecast to 2022Roche 10.6 Genentech, Inc 10.7 GlaxoSmithKline 10.8 Hoffmann-la Roche inc.
Global Gastric Cancer Market Analysis 2016 - Forecast to 2022
Business Wire / Posted 3 days ago
Roche 10.6 Genentech, Inc 10.7 GlaxoSmithKline 10.8 Hoffmann-la Roche inc. 10.9 Immunogen 10.10 Merck KGaA 10.11 Novartis AG 10.12 Oncolytics 10.13 Otsuka Pharmaceutical 10.14 Pacific edge diagnostics NZ 10.15 Roche Holdings AG 10.16... Read more
3d
FOX News
Bristol's Opdivo Boosts Kidney Cancer Survival Beyond 2 Yearsand lung cancer. The U.S. company said in July the study was stopped early bec
Bristol's Opdivo Boosts Kidney Cancer Survival Beyond 2 Years
FOX News / Posted 3 days ago
and lung cancer. The U.S. company said in July the study was stopped early because its drug was more effective than Novartis' established product Afinitor, but detailed results were only disclosed at the European Cancer Congress in Vienna on... Read more
3d
FOX Business
Why Kite Pharma's Stock Is Soaring Todaywhat Based on this positive clinical update, Kite appears to be in the catbird
Why Kite Pharma's Stock Is Soaring Today
FOX Business / Posted 3 days ago
what Based on this positive clinical update, Kite appears to be in the catbird seat in terms of beating its CAR-T rivalsNovartis(NYSE: NVS) and Juno Therapeutics(NASDAQ: JUNO) to market. Novartis, despite restructuring its CAR-T program... Read more
7 related stories
3d
FOX Business
Why Kite Pharma's Stock Is Soaring Todayon this positive clinical update, Kite appears to be in the catbird seat in ter
Why Kite Pharma's Stock Is Soaring Today
FOX Business / Posted 3 days ago
on this positive clinical update, Kite appears to be in the catbird seat in terms of beating its CAR-T rivalsNovartis(NYSE: NVS) and Juno Therapeutics(NASDAQ: JUNO) to market. Novartis, despite restructuring its CAR-T program... Read more
7 related stories
3d
CNBC
Mylan CEO's testimony was a huge blow to the entire pharma industrysimply buying drugs from others. Yet those who have committed to research witho
Mylan CEO's testimony was a huge blow to the entire pharma industry
CNBC / Posted 3 days ago
simply buying drugs from others. Yet those who have committed to research without hesitation — Merck, Amgen, Genentech and Novartis, just to name a few – have created breakthrough drugs that saved millions of lives and generated high returns on... Read more
3d
BBC News
Counterfeit drugs: 'People are dying every day'rewards. More than 70 drugs companies have signed up to the service, including
Counterfeit drugs: 'People are dying every day'
BBC News / Posted 3 days ago
rewards. More than 70 drugs companies have signed up to the service, including multinationals such as GlaxoSmitKline and Novartis, says Sproxil spokesman Tolulope Gbamolayun, and about 28 million verifications have taken place globally since the... Read more
3d
Boston Globe
Kite cancer treatment notches positive results but questions remainto commercialize CAR-T therapies. If the FDA accepts its application, Kite coul
Kite cancer treatment notches positive results but questions remain
Boston Globe / Posted 3 days ago
to commercialize CAR-T therapies. If the FDA accepts its application, Kite could win approval next year. Behind it are Novartis, which expects to submit its CAR-T treatment in 2017, and Juno Therapeutics, which had to push back its commercial... Read more
7 related stories
4d
Chicago Tribune
FDA approves lower-cost alternative to biotech drug Humirasystem. But currently only one biosimilar cleared by the FDA approval pathway
FDA approves lower-cost alternative to biotech drug Humira
Chicago Tribune / Posted 4 days ago
system. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in the U.S., Novartis' Zarxio, an alternative to Amgen's Neupogen that sells for about 15 percent less than the original product. The drug... Read more
2 related stories
4d
The Columbian
Microsoft to help cancer doctorsdirector, Brian Druker, best known for pioneering Gleevec, a blockbuster drug f
Microsoft to help cancer doctors
The Columbian / Posted 4 days ago
director, Brian Druker, best known for pioneering Gleevec, a blockbuster drug for a different type of leukemia now owned by Novartis, that’s helped double those patients’ five-year survival rate since the 1990s. Cancer is caused by genetic... Read more
4d
FOX News
Fda Approves Amgen's Copy Of Abbvie Arthritis Drug Humirato be approved by the FDA and is expected to be sold at a discount to the origi
Fda Approves Amgen's Copy Of Abbvie Arthritis Drug Humira
FOX News / Posted 4 days ago
to be approved by the FDA and is expected to be sold at a discount to the original drug. Last month the agency approved Novartis AG's biosimilar version of Amgen's arthritis drug, Enbrel. Unlike generics, which are interchangeable with their... Read more
2 related stories
4d
Swissinfo
Swiss blue chips: US staff favour Republicansmoney comes from financial companies UBS, Zurich and Credit Suisse, along with
Swiss blue chips: US staff favour Republicans
Swissinfo / Posted 4 days ago
money comes from financial companies UBS, Zurich and Credit Suisse, along with the two biggest Swiss drug companies, Novartis and Roche, and agribusiness giant Syngenta. A closer look at the campaign finance data, however, reveals an... Read more
4d
Arkansas Democrat-Gazette
Microsoft AI project created to customize cancer treatmentsdirector, Brian Druker, best known for pioneering Gleevec, a blockbuster drug f
Microsoft AI project created to customize cancer treatments
Arkansas Democrat-Gazette / Posted 4 days ago
director, Brian Druker, best known for pioneering Gleevec, a blockbuster drug for a different type of leukemia now owned by Novartis, which has helped double those patients' five-year survival rate since the 1990s. Cancer is caused by genetic... Read more
5d
News-Medical-Net
Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseasesNovartis announced today that the US Food and Drug Administration (FDA) has gra
Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases
News-Medical-Net / Posted 5 days ago
Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris® (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. Ilaris is the first... Read more
5d
Sydney Morning Herald
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Sydney Morning Herald / Posted 5 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
5d
WA Today
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
WA Today / Posted 5 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
5d
Brisbane Times
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Brisbane Times / Posted 5 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
Business Wire
Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1demonstrated commitment to RNAi therapeutics has enabled it to form major allia
Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1
Business Wire / Posted 6 days ago
demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche, Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity... Read more
6d
Northern Daily Leader
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Northern Daily Leader / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
The Young Witness
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
The Young Witness / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
Western Advocate
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Western Advocate / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
Kiama Independent
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Kiama Independent / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
Manning River Times
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Manning River Times / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
Goondiwindi Argus
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Goondiwindi Argus / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
The North West Star
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
The North West Star / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
Daily Liberal
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
Daily Liberal / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
The Border Mail
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
The Border Mail / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
The Courier
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
The Courier / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
The Seattle Times
FDA approves lower-cost alternative to biotech drug Humirasystem. But currently only one biosimilar cleared by the FDA approval pathway
FDA approves lower-cost alternative to biotech drug Humira
The Seattle Times / Posted 6 days ago
system. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in the U.S., Novartis’ Zarxio, an alternative to Amgen’s Neupogen that sells for about 15 percent less than the original product. The drug... Read more
5 related stories
6d
The Age
How big pharma spent $650k on Australian nurses in six monthsSquibb spent at least $120,000 on nurses over the period, the most amount discl
How big pharma spent $650k on Australian nurses in six months
The Age / Posted 6 days ago
Squibb spent at least $120,000 on nurses over the period, the most amount disclosed of all companies, followed by Novartis ($82,642), Gilead ($72,899), and Pfizer ($53,767). A Bristol-Myers Squibb spokeswoman said the company had a... Read more
14 related stories
6d
WDIO Duluth
FDA Approves Lower-Cost Alternative to Biotech Drug Humirasystem. But currently only one biosimilar cleared by the FDA approval pathway
FDA Approves Lower-Cost Alternative to Biotech Drug Humira
WDIO Duluth / Posted 6 days ago
system. But currently only one biosimilar cleared by the FDA approval pathway is actually on the market in the U.S., Novartis' Zarxio, an alternative to Amgen's Neupogen that sells for about 15 percent less than the original product. The drug... Read more
5 related stories
6d
Pacific Coast Business Times
FDA approves Amgen biosimilar of AbbVie’s HumiraFDA approved a copycat version of Amgen’s Enbrel and allowed a competitor to ta
FDA approves Amgen biosimilar of AbbVie’s Humira
Pacific Coast Business Times / Posted 6 days ago
FDA approved a copycat version of Amgen’s Enbrel and allowed a competitor to take a shot at it. Made by Switzerland-based Novartis, Erelzi mimics the effects of Enbrel. Enbrel, which was first approved in 1998, is approved to treat rheumatoid... Read more
5 related stories
7d
The Economic Times
Sun Pharmaceuticals among bidders for Bayer’s dermatology brandsfor buyouts at an aggressive pace, according to an investment banker. Earlier
Sun Pharmaceuticals among bidders for Bayer’s dermatology brands
The Economic Times / Posted 7 days ago
for buyouts at an aggressive pace, according to an investment banker. Earlier this year, it bought a set of brands from Novartis in Japan for $293 million. If Sun Pharma advances into the next stages of the process and clinches Bayer's... Read more
8d
Investors Chronicle
New GSK chief - what will be expected of Emma Walmsley?She joined the GSK consumer health team in 2010 and became the chief executive
New GSK chief - what will be expected of Emma Walmsley?
Investors Chronicle / Posted 8 days ago
She joined the GSK consumer health team in 2010 and became the chief executive of the consumer health joint venture with Novartis when it was created in 2015. Philip Hampton, GSK's chairman, described Ms Walmsley as an "outstanding leader" with... Read more
57 related stories
9d
FOX Business
The Most Exciting Drug In Celgene's Pipelineoral Tecfidera has been associated with increased risk of a rare and serious br
The Most Exciting Drug In Celgene's Pipeline
FOX Business / Posted 9 days ago
oral Tecfidera has been associated with increased risk of a rare and serious brain infection called PML. Finally, Novartis' Gilenya, another S1P drug on the market for MS, carries warnings on its label about the potential for heart... Read more
9d
FOX Business
The Most Exciting Drug In Celgene's Pipelineoral Tecfidera has been associated with increased risk of a rare and serious br
The Most Exciting Drug In Celgene's Pipeline
FOX Business / Posted 9 days ago
oral Tecfidera has been associated with increased risk of a rare and serious brain infection called PML. Finally, Novartis' Gilenya, another S1P drug on the market for MS, carries warnings on its label about the potential for heart... Read more
9d
Reuters
Divided U.S. Supreme Court turns to less sensitive IP casesto file briefs offering its opinion on whether they should be taken up. One cl
Divided U.S. Supreme Court turns to less sensitive IP cases
Reuters / Posted 9 days ago
to file briefs offering its opinion on whether they should be taken up. One closely-watched case on that list concerns Novartis AG's(NOVN.S) bid to launch a copycat version of Amgen Inc's(AMGN.O) cancer drug Neupogen, which IP law experts say... Read more
20 related stories
More

People in this news